Immunocore, Adaptimmune and UPenn researchers have determined that off-target toxicity most likely caused the two fatalities in a cancer trial of affinity-enhanced T cell receptors. The results highlight the need for using biologically appropriate disease models and deep molecular analyses to minimize cross-reactivity-related toxicity in future adoptive immunotherapy trials.